Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.
Publication
, Journal Article
Lou, E; Reardon, DA; Peters, K; Desjardins, A; Herndon, JE; Coan, AD; Turner, SG; Sumrall, AL; Bailey, L; Friedman, HS; Vredenburgh, JJ
Published in: Journal of Clinical Oncology
May 20, 2011
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
2055 / 2055
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lou, E., Reardon, D. A., Peters, K., Desjardins, A., Herndon, J. E., Coan, A. D., … Vredenburgh, J. J. (2011). Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology, 29(15_suppl), 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055
Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055.
Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):2055–2055.
Lou, E., et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 2055–2055. Crossref, doi:10.1200/jco.2011.29.15_suppl.2055.
Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, Turner SG, Sumrall AL, Bailey L, Friedman HS, Vredenburgh JJ. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):2055–2055.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
2055 / 2055
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences